Hemogenyx Pharmaceuticals Plc (HEMO.L)

1.5650 -0.0020 (-0.13%) At close: 04:20PM BST

Hemogenyx Pharmaceuticals Plc

60 Gracechurch Street
6th Floor
London EC3V 0HR
United Kingdom

https://www.hemogenyx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Vladislav Sandler Ph.D.	Co-Founder, CEO & Director	282k	N/A	1965
Ms. Alexis M. Sandler J.D.	Independent Co-Founder & Non-Executive Director	57k	N/A	1976
Dr. Koen Van Besien M.D., Ph.D.	Clinical Advisor & Medical Director	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Corporate governance

Hemogenyx Pharmaceuticals Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.